• -

TENS PEMF therapy in the management of Cancer

The following studies represent some of the clinical evidence for the use of TENS PEMF therapy in the management of Cancer.

PEMF therapy for drug resistant cancer

Please note that these studies were not done on the Rife PEMF device, but rather represent studies including outputs which can be found on the various Rife Model MA devices.

ELF Magnetic field induce tumor growth inhibition and apoptosis Significant tumor growth inhibition – up to 50%. No effect on normal healthy cells. ELF at 50Hz for four weeks.
Growth of injected melanoma cells is suppressed by whole body exposure to specific spatial-temporal configurations of weak intensity magnetic fields Mice exposed to the field that was rotated through the three spatial dimensions and through all three planes every 2 sec did not grow tumors after 38 days. However, the mice in the sham-field and reference controls showed massive tumors after 38 days. Tumor growth was also affected by the intensity of the field, with mice exposed to a weak intensity field (1-5 nT) forming smaller tumors than mice exposed to sham or stronger, high intensity (2-5 microT) fields.
Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields Treatment with intrabuccally administered amplitude-modulated electromagnetic fields is safe, well tolerated, and shows

evidence of antitumor effects in patients with advanced HCC.

410 – 642Hz very low AM ELF
Low Intensity and Frequency Pulsed Electromagnetic

Fields Selectively Impair Breast Cancer Cell Viability

We observed a discrete window of vulnerability of MCF7 cells to PEMFs of 20 Hz frequency, 3 mT magnitude and

exposure duration of 60 minutes per day. The cell damage accrued in response to PEMFs increased with time and gained

significance after three days of consecutive daily exposure. By contrast, the PEMFs parameters determined to be most

cytotoxic to breast cancer MCF-7 cells were not damaging to normal MCF-10 cells.

20Hz 3mT daily for 60 minutes a day
Mechanisms and therapeutic effectiveness of pulsed

electromagnetic field therapy in oncology

 In vitro studies support antineoplastic and antiangiogenic

effects of PEMF therapy. Several mechanisms of PEMF

therapy have been elucidated. For example, PEMFs inhibit

cancer growth by disrupting the mitotic spindle in a process

mediated by interference of spindle tubulin orientation

and induction of dielectrophoresis. Furthermore, PEMF

therapy modulates gene expression and protein synthesis interacting with specific DNA sequences within gene promoter

regions [18, 38, 40, 41, 58, 103]. In addition, PEMFs

inhibit angiogenesis in tumor tissues, suppressing tumor

vascularization and reducing tumor growth, as shown by

in vivo studies [95-99, 104].

The specific claim, supported by the described in vivo

studies, is that all treated groups showed slower tumor

growth rate if compared with untreated control group,

confirming that PEMF therapy can modulate the physiology

and electrochemistry of cancer cells and influence

cell membrane systems and mitosis. In addition, PEMFs

induce some changes in membrane transport capacity

through impacting the osmotic potential, ionic valves and

leading to reduction in cellular stress factors, increase in

the rate of DNA transcription, and modulation of immune

response [105].

PEMFs have also an immunomodulatory effect, as supported

by in vivo evidence showing an increase in tumor

necrosis factor alpha levels that induce an anti-tumoral

response, leading to the activation of a proapoptotic pathway

induced by caspase-8 interaction with Fas-associated

death domain, in the spleen of the murine melanoma

mouse model after a 16-day therapy [78]. Changes in

blood pressure, skin electrical resistance, and pulse amplitude

in 163 oncology patients exposed to tumor-specific

PEMF frequencies have also been reported suggesting that

PEMF therapy does not only target neoplastic cells, but

may also have systemic effects [15]. However, long-term

PEMF treatment in HCC patients is not toxic, confirming

the safety of PEMF therapy that employs 100,000 times

lower frequencies if compared with radiofrequency ablation

that is also employed for treatment of HCC [55].

In conclusion, two clinical studies have used

PEMF therapy for cancer treatment. These studies show

that PEMF therapy is safe and promising compared to

other available cancer therapies. In the future, PEMFs

could be used not only as primary therapy but also in

combination with other common antineoplastic therapies.

Given that new portable and affordable PEMF devices

are increasingly available on the market, future controlled

clinical studies are expected to further determine the

potential of PEMF therapy in oncology

PMF sensitized fibrosarcoma and hepatocellular carcinoma to mitomycin C An article published in the Japanese Journal of Cancer research, investigated the effects of PMF therapy in combination with mitomycin C for the treatment of fibrosarcoma and hepatocellular carcinoma.[1]

WKA rats were exposed to a frequency of 200Hz immediately after IV injections of mitomycin C. The survival rates of the rats were recorded. Cultured cells were also used to study the efficacy of PMF and mitomycin C, and a combination of the two.

Survival rates of the untreated rats were 0% in the non-treated group, 34% in the group treated with mitomycin C only, and 47% for the PMF only group. For the group who received a combination of PMF and mitocycin C, the survival rate was 77%. The combination increased lifespan of the PMF mitomycin C group which was significantly prolonged at 17,6%. The efficiencies of the cells in the cultures of both cell lines were also significantly suppressed in the combination therapy group when compared with those in the other single therapy groups.

This study clearly indicates the possibility that PEMF therapy could improve and enhance the efficacy of drugs like mitomycin C.

Low frequency EMF sensitizes cisplatin-resistant ovarian adenocarcinoma


Platinum based drugs like cisplatin often form the first line of therapy for cancers including testicular, bladder, esophageal cancer, lung cancer, mesothelioma, brain tumors, neuroblastoma ovarian and colorectal tumors but the use of cisplatin also often results in chemotherapy resistant cancers.[2]

In the search for a way to re-sensitize cancers to cisplatin, researchers investigated the use of extra-low frequency electromagnetic field therapy on cisplatin-resistant A2780 ovarian cancer cells. Cells were exposed to 200hz at 50 Gauss.

Researchers found that EL-EMF decreased proliferation of the cells independently of cisplatin. They also saw a decreased proliferation rate of 40 % in the cisplatin only group but the cells treated with a combination of cisplatin and EL-EMF showed a 71 % decrease in viability in rats.[3] They also saw a large increase in late apoptosis in the combination group as indicated in the graph below:

Histogram from percentage of live and dead cells from AO/PI staining for A2780 cells, data are presented as means (±SD)

The study concluded that EL-EMF therapy at 200Hz can help to sensitize cancer cells to cisplatin and improved the efficacy of cisplatin.


Pulsed magnetic fields enhance the potency of daunorubicin in human carcinoma cell lines


Researchers studied the effects of PMF pulses of 250Hz on multidrug resistant human carcinoma cells. They inoculated mice with a multidrug resistant form of human carcinoma. They then treated the resultant tumors with pulsed magnetic therapy only or a combination of PMF therapy and daunorubicin.

Researchers found that amongst the various groups, significant differences in the tumor volume were found between PMF + saline and PMF + daunorubicin groups at 39 days and 42 days. No mice died in the PMF alone group, and no toxicity attributable to PMF was found during the experimental period.

The results indicated that the efficacy of daunorubicin was potentiated in vitro by PMF exposure when PMF exposure occurred in the presence of the drug.

PEMF improves the effects of doxorubicin in Osteosarcoma


In another study, researchers studied the potential drug resistance modification effects of PEMF stimulation in multidrug resistant mouse osteosarcoma. PEMF stimulation reversed doxorubicin resistance. The concluded that PEMFs reversed the doxorubicin resistance of the MOS/ADR1 cells by inhibiting P-gp function. The results suggested that PEMFs may be useful as a local treatment for multidrug resistant osteosarcoma
50Hz enhances the antiproliferative effects of 5-fluorouracil in breast cancer


Finally, researchers explored the effects of pre-exposure to 50Hz to help to reduce resistance to 5-fluorouracil to enhance efficacy of the drug. The study explored the combined effect of 50 Hz-EMFs and 5-FU in the treatment of breast cancer.

Researchers found that pre-exposure to 50 Hz-EMFs enhanced the antiproliferative effect of 5-FU in breast cancer cell line MCF-7 in a dose-dependent manner but did not affect normal human breast epithelial cell lines.

They concluded that the enhanced cytotoxic activity of 5-FU on MCF7 cells through promoting entry into the S phase of the cell cycle via exposure to 50 Hz-EMFs, may provide a novel method of cancer treatment based on the combinatorial use of 50 Hz-EMFs and chemotherapy.


[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918102/

[2] https://www.ncbi.nlm.nih.gov/pubmed/21892204

[3] https://www.ncbi.nlm.nih.gov/pubmed/26370097

For more information on cancer and drug resistance please read

The Rife PEMF Model MA200 Cancer Protocol

PEMF therapy for drug resistant cancer

PEMF in cancer therapy – PEMF could be a promising modality

For more information, research and studies on TENS PEMF therapy in the management of Cancer, please join our newsletter or check back regularly for updates.